

Microenvironment of diabetic foot ulcers: Implications for healing and therapeutic strategies

Jixue Wang¹, Xirui Yang², Tao Zhou¹, Haitao Ma¹, Xingxing Yuan³, Shuxun Yan⁴, Siqi Wang⁵

¹Department of Peripheral Vascular Medicine, First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan Province, China, ²Department of Ophthalmology, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan Province, China, ³Department of Medicine, Heilongjiang Academy of Traditional Chinese Medicine, Harbin, Heilongjiang, China, ⁴Department of Endocrinology, First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan Province, China, ⁵Department of Medicine, First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan Province, China

Diabetic foot ulcers (DFUs) are a common yet serious complication in individuals with diabetes, often presenting as chronic, nonhealing wounds that significantly impair quality of life. The healing process of DFUs is largely influenced by the local microenvironment, which encompasses factors such as hypoxia, inflammation, and the involvement of various cell types. Poor blood circulation in the affected area results in hypoxia, compromising cellular function and restricting nutrient supply, thereby delaying wound healing. In addition, chronic inflammation disrupts immune system balance, with excessive pro-inflammatory cytokines not only failing to facilitate tissue repair but also exacerbating tissue damage. Moreover, key cell types, including fibroblasts, keratinocytes, and macrophages, play crucial roles at different stages of the healing process, contributing to collagen production and skin regeneration. A comprehensive understanding of the complex dynamics within the DFU microenvironment is essential for developing more precise therapeutic approaches, such as advanced drug delivery systems and bioactive materials, aimed at promoting wound healing and reducing the risk of recurrence.

Key words: Diabetic foot ulcers, hypoxia, inflammation, microenvironment, wound healing

How to cite this article: Wang J, Yang X, Zhou T, Ma H, Yuan X, Yan S, *et al.* Microenvironment of diabetic foot ulcers: Implications for healing and therapeutic strategies. *J Res Med Sci* 2025;30:19.

INTRODUCTION

Diabetic foot ulcers (DFUs) pose a significant health challenge for individuals with diabetes, resulting in a considerable burden on healthcare systems.^[1] These chronic wounds often lead to serious complications, such as infections, prolonged hospitalization, and even lower limb amputation. The prevalence of DFUs is alarming, with studies suggesting that up to 25% of diabetic patients will develop a foot ulcer during their lifetime.^[2] The multifactorial nature of DFUs makes them particularly challenging to treat, as various intrinsic and extrinsic factors interplay to impede the healing process.^[3]

A critical determinant of healing outcomes in DFUs is the local microenvironment, which is markedly

different from that of acute wounds.^[4] In contrast to acute wounds, which typically progress through a well-defined healing cascade, DFUs often exhibit a persistent inflammatory response characterized by elevated levels of pro-inflammatory cytokines and immune cell infiltration.^[5] This prolonged inflammation results in a cycle of tissue damage and repair that can become dysregulated, ultimately delaying healing.

Another significant aspect of the DFU microenvironment is hypoxia, which arises from inadequate blood flow and perfusion.^[6] Hypoxia not only limits the availability of oxygen and essential nutrients but also disrupts the normal functioning of key cellular players involved in healing, including fibroblasts and keratinocytes.^[7] Furthermore, impaired angiogenesis – the formation of

Access this article online

Quick Response Code:



Website:

<https://journals.lww.com/jrms>

DOI:

10.4103/jrms.jrms_573_24

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Address for correspondence: Prof. Tao Zhou, Department of Peripheral Vascular Medicine, First Affiliated Hospital of Henan University of Traditional Chinese Medicine, No. 19, Renmin Road, Zhengzhou, Henan Province, China.

E-mail: zwxgzt@163.com

Submitted: 06-Oct-2024; **Revised:** 24-Feb-2025; **Accepted:** 12-Mar-2025; **Published:** 29-Mar-2025

new blood vessels – exacerbates the hypoxic conditions and hinders the delivery of healing factors to the wound site.^[8,9]

The cellular composition of the DFU microenvironment is complex and includes various cell types, such as fibroblasts, keratinocytes, macrophages, and endothelial cells.^[10] Each of these cells plays distinct yet interconnected roles in the healing process. For instance, fibroblasts are responsible for collagen deposition and extracellular matrix (ECM) remodeling, while keratinocytes are essential for re-epithelialization. Macrophages, on the other hand, not only mediate inflammation but also orchestrate the transition from inflammation to repair by secreting growth factors that promote tissue regeneration.^[11]

Biochemical factors, including growth factors and cytokines, further modulate the healing process by influencing cell proliferation, migration, and ECM synthesis.^[12] The ECM itself provides a structural framework that supports cellular attachment and migration, facilitating the healing process. Dysregulation of these biochemical signals can lead to a failure in the proper healing response, prolonging the ulcerative state.^[13,14]

In this review, we focus on the intricate local microenvironment of DFUs, aiming to elucidate how these cellular and biochemical factors interact to contribute to delayed healing. We will explore the specific cellular components present in the DFU microenvironment, the impact of chronic inflammation and hypoxia, and the critical role of the ECM in wound healing. By understanding these dynamics, we can identify potential therapeutic targets that may enhance healing and improve outcomes for patients suffering from DFUs.

CELLULAR COMPOSITION OF THE DIABETIC FOOT ULCER MICROENVIRONMENT

The cellular landscape of DFUs is intricate and multifaceted, composed of a diverse array of cell types that interact dynamically to mediate the healing process.^[10] Fibroblasts are pivotal in synthesizing and remodeling the ECM, which provides structural support and regulates cellular behavior.^[11] They produce key ECM components, such as collagen, elastin, and proteoglycans, which are essential for maintaining tissue integrity and facilitating cell migration during the healing process.^[15] In DFUs, fibroblast activity is often diminished due to the hostile microenvironment characterized by chronic inflammation and hypoxia, leading to inadequate ECM deposition and impaired wound closure.^[16]

Keratinocytes, which are primarily responsible for re-epithelialization, also play a critical role in DFU

healing.^[17] They migrate across the wound bed to cover the defect, and their proliferation is influenced by growth factors present in the microenvironment.^[18] In the context of DFUs, keratinocyte function can be impaired by the persistent inflammatory milieu and the lack of appropriate signaling cues, which can delay the re-epithelialization process.^[19]

Macrophages, another key cellular component, have a dual role in the healing process.^[20] These cells can exist in different polarization states: M1 macrophages, which are pro-inflammatory, and M2 macrophages, which promote tissue repair and resolution of inflammation. In DFUs, an accumulation of M1 macrophages can perpetuate inflammation, leading to tissue damage and impaired healing.^[21] Conversely, M2 macrophages facilitate the transition to a regenerative state through the secretion of growth factors and cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF- β), which are essential for tissue repair and angiogenesis.^[18] The ability to modulate macrophage polarization within the DFU microenvironment could therefore provide a novel therapeutic strategy to enhance healing by promoting the shift from the pro-inflammatory to the reparative phase.^[22]

Endothelial cells are also integral to the healing process, as they are critical for angiogenesis—the formation of new blood vessels. In DFUs, impaired angiogenesis often results from chronic hypoxia and inflammation, further limiting oxygen and nutrient supply to the healing tissue.^[23,24] The interplay between endothelial cells and macrophages is significant; for example, macrophages can secrete angiogenic factors that stimulate endothelial cell proliferation and migration, thereby facilitating new blood vessel formation.^[25,26] Table 1 summarizes the roles of different cell types involved in the healing process of DFUs.

Impact of inflammation on wound healing

Inflammation plays a fundamental role in the wound healing process, yet its impact can be a double-edged sword. Acute inflammation is necessary for clearing debris, preventing infection, and initiating the healing cascade.^[27] In contrast, chronic inflammation, which is frequently observed in DFUs, can significantly hinder the healing process. Persistent inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α), interleukin-1 beta (IL-1 β), and interleukin-6 (IL-6) are elevated in DFUs, disrupting the normal healing cascade.^[28] These cytokines can delay re-epithelialization, inhibit fibroblast function, and impede angiogenesis, ultimately leading to prolonged wound healing and an increased risk of complications.^[29]

Research indicates that targeting inflammatory pathways may improve healing outcomes in DFUs. For instance, the

Table 1: Cellular dynamics in the healing process of diabetic foot ulcers

Cell type	Role in healing	Challenges in DFUs	Key interactions
Fibroblasts	Synthesize and remodel the ECM Produce collagen, elastin, and proteoglycans for tissue integrity and cell migration	Activity often diminished due to chronic inflammation and hypoxia Leads to inadequate ECM deposition and impaired wound closure	Interacts with keratinocytes and macrophages to regulate healing processes
Keratinocytes	Responsible for re-epithelialization Migrate to cover the wound defect; proliferation influenced by growth factors	Function can be impaired by persistent inflammation and lack of signaling cues Delays the re-epithelialization process	Influenced by growth factors secreted by fibroblasts and macrophages
Macrophages	Dual roles: M1 (pro-inflammatory) and M2 (promoting tissue repair) M2 macrophages secrete growth factors (e.g., IL-10, TGF- β) essential for tissue repair and angiogenesis	Accumulation of M1 macrophages perpetuates inflammation and tissue damage Need for modulation of polarization to enhance healing	M1 macrophages can inhibit endothelial cell function; M2 macrophages promote angiogenesis and recruit fibroblasts
Endothelial cells	Critical for angiogenesis (formation of new blood vessels)	Impaired angiogenesis due to chronic hypoxia and inflammation Limits oxygen and nutrient supply to healing tissue	Interacts with macrophages, which can secrete angiogenic factors to stimulate endothelial cell proliferation and migration

ECM=Extracellular matrix; TGF- β =Transforming growth factor-beta; DFUs=Diabetic foot ulcers

use of anti-inflammatory agents such as corticosteroids or novel biologics could potentially modulate the inflammatory response, promoting a shift toward a more regenerative environment.^[30,31] In addition, the application of localized therapies that can reduce inflammation at the wound site, such as cytokine inhibitors or mesenchymal stem cells, may facilitate a transition from the chronic inflammatory phase to the proliferative phase of healing.^[32]

Furthermore, the concept of inflammation resolution is gaining traction as a critical aspect of wound healing. Effective resolution of inflammation involves the transition from pro-inflammatory signals to anti-inflammatory signals, allowing for the restoration of tissue homeostasis. Strategies that enhance the resolution phase of inflammation, such as the administration of resolvins or protectins, may hold promise for promoting healing in chronic wounds.^[33]

Hypoxia and its role in diabetic foot ulcers

Hypoxia is a prevalent feature of DFUs, primarily resulting from reduced blood flow and impaired angiogenesis.^[34] Oxygen is crucial for cellular metabolism, and it plays a significant role in the production of essential growth factors that drive the healing process. Under hypoxic conditions, the expression of hypoxia-inducible factor 1- α (HIF-1 α) is increased, which orchestrates a range of adaptive responses, including angiogenesis and glycolysis.^[35,36] While HIF-1 α is essential for initiating reparative processes, chronic hypoxia can lead to maladaptive responses, promoting fibrosis and inhibiting effective healing.^[37]

This chronic hypoxia presents an even greater challenge in DFUs, as it negatively affects the function of key cellular players that are essential for healing. For example, fibroblasts, which are responsible for collagen production and ECM remodeling, show reduced functionality under prolonged low-oxygen conditions, leading to inadequate

ECM deposition and impaired wound closure.^[38] Moreover, hypoxic conditions can exacerbate the inflammatory response by promoting the recruitment of inflammatory cells to the wound site, further complicating the healing process.^[39,40]

Strategies aimed at alleviating hypoxia may offer promising avenues for enhancing healing in DFUs. For example, hyperbaric oxygen therapy has been shown to improve tissue oxygenation and stimulate angiogenesis, leading to accelerated wound healing in chronic ulcers. In addition, the application of oxygen-releasing materials or the use of topical agents that enhance oxygen delivery to the wound site may also improve healing outcomes by restoring oxygen levels and promoting a more favorable microenvironment for cellular activities.^[41]

Extracellular matrix dynamics

The ECM is fundamental to wound healing, providing structural support and regulating cellular behavior.^[42] In DFUs, the composition and organization of the ECM are often disrupted, contributing to impaired healing.^[43] Key components of the ECM, such as collagen and glycosaminoglycans, are essential for maintaining tissue integrity and facilitating cellular migration.

In DFUs, the deposition of collagen is frequently inadequate, leading to the formation of weak and disorganized scar tissue.^[44] Moreover, the degradation of the ECM is frequently accelerated due to elevated matrix metalloproteinases and reduced levels of tissue inhibitors of metalloproteinases, resulting in a net loss of ECM components. This imbalance contributes to a dysfunctional healing response and increases the risk of ulcer recurrence.^[45]

To address these ECM-related challenges, modulating ECM dynamics through the application of biomaterials

or growth factors may provide a potential therapeutic approach to enhance tissue regeneration. For instance, the use of collagen-based dressings or scaffolds can provide a supportive environment for cell attachment and migration while delivering bioactive agents to the wound site.^[46] Recent advances in tissue engineering, including the use of three-dimensional (3D) bioprinting and smart biomaterials, hold promise for creating an optimal ECM environment conducive to healing.^[47] These technologies allow for the fabrication of personalized scaffolds that mimic the native tissue architecture and biochemical composition, thereby enhancing the regenerative potential of the wound-healing process.

Therapeutic approaches targeting the microenvironment

Given the complexity of the DFU microenvironment, multifaceted therapeutic approaches are necessary to promote effective healing. Strategies such as local delivery of growth factors can enhance specific aspects of the healing process. For example, the administration of vascular endothelial growth factor (VEGF) can stimulate angiogenesis, while fibroblast growth factor can promote fibroblast proliferation and ECM deposition.^[48,49]

Nanotechnology also offers innovative solutions for targeted drug delivery in DFUs.^[48] Nanocarriers can encapsulate therapeutic agents, facilitating controlled release at the wound site and enhancing bioavailability. By modifying the surface characteristics of nanocarriers, it is possible to achieve selective targeting of specific cell types within the microenvironment, improving the efficacy of treatment.

Advanced wound dressings play a crucial role in maintaining a moist environment, which is essential for promoting healing and preventing desiccation of the ulcer.^[50] These dressings can incorporate bioactive agents, such as antimicrobial peptides or growth factors, to further enhance their therapeutic properties.^[51] In addition, incorporating smart materials that respond to changes in

the wound microenvironment (e.g. pH or temperature) can optimize drug release profiles, ensuring that therapeutic agents are delivered precisely when and where they are needed.

Furthermore, stem cell therapy has emerged as a promising option to replenish damaged tissue and modulate the microenvironment.^[13] Stem cells possess the ability to differentiate into various cell types involved in wound healing and can secrete a range of bioactive factors that promote tissue regeneration.^[15,52] Future research should focus on integrating these therapeutic modalities to develop comprehensive treatment plans tailored to individual patient needs. Personalized approaches that consider the unique characteristics of each DFU, including its size, depth, and surrounding microenvironment, will be essential for optimizing healing outcomes and reducing recurrence rates. Table 2 summarizes the intricate relationship between inflammation, hypoxia, and ECM dynamics in DFUs, highlighting potential therapeutic approaches for improved wound healing.

DISCUSSION

The local microenvironment of DFUs is multifaceted and critical for determining healing outcomes.^[53] A comprehensive understanding of this microenvironment, encompassing cellular components, biochemical factors, and physical characteristics, is essential for developing effective therapeutic strategies. DFUs represent a unique challenge due to their chronic nature, where the interplay between various factors often leads to delayed healing and increased risk of complications, such as infections and amputations.^[54]

The cellular composition of the DFU microenvironment is a fundamental aspect that dictates healing trajectories.^[55] Fibroblasts and keratinocytes are integral for ECM synthesis and re-epithelialization, respectively, while macrophages

Table 2: Impact of inflammation, hypoxia, and extracellular matrix dynamics on wound healing in diabetic foot ulcers

Aspect	Description	Key points
Inflammation	Inflammation plays a crucial role in wound healing, with acute inflammation being beneficial while chronic inflammation hinders the process	Chronic inflammation in DFUs is marked by elevated cytokines (e.g., TNF- α , IL-1 β) Anti-inflammatory therapies may improve healing outcomes
Hypoxia	Hypoxia, due to reduced blood flow and impaired angiogenesis, hampers the wound healing process by affecting key cellular functions	Chronic hypoxia can lead to maladaptive responses and exacerbate inflammation Strategies to alleviate hypoxia include hyperbaric oxygen therapy and topical agents
ECM	The ECM is vital for providing structural support and regulating cellular behavior, with its dynamics significantly impacting healing outcomes	Impaired collagen deposition and accelerated ECM degradation occur in DFUs Modulating ECM dynamics with biomaterials and growth factors may enhance healing
Therapeutic approaches	Multifaceted strategies, including growth factor delivery, nanotechnology, advanced dressings, and stem cell therapy, are necessary to optimize healing in DFUs	Local delivery of VEGF and FGF can stimulate angiogenesis and fibroblast activity Smart materials and nanocarriers enhance treatment efficacy

VEGF=Vascular endothelial growth factor; ECM=Extracellular matrix; DFUs=Diabetic foot ulcers; FGF=Fibroblast growth factor; TNF=Tumor necrosis factor

serve as central regulators of inflammation and tissue repair.^[56] The dual role of macrophages is particularly noteworthy; the transition from pro-inflammatory M1 macrophages to reparative M2 macrophages is critical for moving the wound from a chronic inflammatory state to a regenerative phase.^[57] Research shows that manipulating macrophage polarization can significantly impact healing outcomes, suggesting that therapies aimed at promoting this shift could enhance the reparative process.^[58] For instance, the application of M2-inducing cytokines or the use of nanocarriers to deliver these factors locally could be explored as potential therapeutic avenues.^[59]

Inflammation is a double-edged sword in the wound-healing process.^[60] While acute inflammation is necessary for clearing debris and preventing infection, chronic inflammation, as seen in DFUs, impedes the healing cascade.^[61] The persistent presence of inflammatory cytokines such as TNF- α , IL-1 β , and IL-6 has been implicated in delaying re-epithelialization and angiogenesis. These cytokines not only activate pro-inflammatory pathways but also inhibit key processes such as fibroblast proliferation and angiogenesis. Innovative anti-inflammatory strategies, such as the use of monoclonal antibodies or small molecule inhibitors targeting specific inflammatory pathways, may prove beneficial in curtailing excessive inflammation. Furthermore, understanding the precise timing of intervention is crucial; interventions should be tailored to the specific phases of wound healing to maximize their efficacy without compromising necessary inflammatory responses.^[62] For example, early-phase inhibition of TNF- α may enhance the transition from inflammation to the proliferative phase, while later-phase treatments could focus on modulating M2 macrophage function to accelerate tissue repair.

Chronic hypoxia in DFUs exacerbates the healing challenge by hindering cellular metabolism and growth factor production.^[63] HIF-1 α activates a network of genes involved in angiogenesis, metabolism, and cellular survival under hypoxic conditions. Strategies that enhance tissue oxygenation, such as hyperbaric oxygen therapy, are promising; however, their implementation needs to be evaluated in well-designed clinical trials to ascertain efficacy and safety. Furthermore, the development of oxygen-releasing biomaterials could provide localized solutions to hypoxia, offering a controlled release of oxygen at the wound site.^[64,65]

The ECM is essential for providing structural integrity and biochemical signals necessary for cellular behavior during healing. In DFUs, the ECM is often disorganized, leading to inadequate support for cellular migration and function. Advances in biomaterials and tissue engineering, particularly the use of 3D bioprinting technologies, could

revolutionize DFUs treatment by creating personalized scaffolds that replicate the native ECM.^[66] These scaffolds could incorporate bioactive molecules that promote angiogenesis and cellular proliferation, ultimately enhancing the healing process. Research exploring the interactions between ECM components and cellular signaling pathways is vital for developing effective ECM-targeting strategies.

Given the complexity of the DFU microenvironment, multifaceted therapeutic approaches are necessary. Localized delivery systems that utilize nanotechnology can enhance the precision of drug delivery, allowing for targeted treatment of specific cellular populations within the wound. In addition, combining growth factors with advanced wound dressings that maintain a moist environment can significantly improve healing outcomes. The use of stem cell therapy to replenish damaged tissues and modulate the microenvironment also shows promise, although the logistics of implementing such therapies in clinical practice require further exploration.

In conclusion, understanding the complexities of the DFU microenvironment is paramount for developing innovative and effective therapeutic strategies. By addressing the interplay between cellular dynamics, inflammatory processes, hypoxia, and ECM integrity, researchers can pave the way for novel interventions that not only enhance healing outcomes but also improve the overall quality of life for patients suffering from DFUs. Further investigations into the molecular mechanisms regulating each of these factors, along with the development of targeted therapies, will be key to overcoming the challenges presented by DFUs and advancing clinical care in this area.

Financial support and sponsorship

National Natural Science Foundation of China Youth Fund Project (82205117); Postdoctoral Research Project of Henan Province (HN2024083); Research Special Project of Henan Province Traditional Chinese Medicine Clinical Research Base (2022JDZX135).

Conflicts of interest

There is no conflict of interests.

REFERENCES

1. Everett E, Mathioudakis N. Update on management of diabetic foot ulcers. *Ann N Y Acad Sci* 2018;1411:153-65.
2. Rehman ZU, Khan J, Noordin S. Diabetic foot ulcers: Contemporary assessment and management. *J Pak Med Assoc* 2023;73:1480-7.
3. Alavi A, Sibbald RG, Mayer D, Goodman L, Botros M, Armstrong DG, *et al.* Diabetic foot ulcers: Part I. Pathophysiology and prevention. *J Am Acad Dermatol* 2014;70:18.e1-18.
4. Huang F, Lu X, Yang Y, Yang Y, Li Y, Kuai L, *et al.* Microenvironment-based diabetic foot ulcer nanomedicine. *Adv Sci (Weinh)* 2023;10:e2203308.

5. Theocharidis G, Thomas BE, Sarkar D, Mumme HL, Pilcher WJ, Dwivedi B, *et al.* Single cell transcriptomic landscape of diabetic foot ulcers. *Nat Commun* 2022;13:181.
6. Catrina SB, Zheng X. Hypoxia and hypoxia-inducible factors in diabetes and its complications. *Diabetologia* 2021;64:709-16.
7. Shang L, Yu Y, Jiang Y, Liu X, Sui N, Yang D, *et al.* Ultrasound-augmented multienzyme-like nanzyme hydrogel spray for promoting diabetic wound healing. *ACS Nano* 2023;17:15962-77.
8. Liu Y, Liu Y, Deng J, Li W, Nie X. Fibroblast growth factor in diabetic foot ulcer: Progress and therapeutic prospects. *Front Endocrinol (Lausanne)* 2021;12:744868.
9. Rai V, Moellmer R, Agrawal DK. Role of fibroblast plasticity and heterogeneity in modulating angiogenesis and healing in the diabetic foot ulcer. *Mol Biol Rep* 2023;50:1913-29.
10. Chen R, Zou L. Combined analysis of single-cell sequencing and bulk transcriptome sequencing reveals new mechanisms for non-healing diabetic foot ulcers. *PLoS One* 2024;19:e0306248.
11. Li Y, Ju S, Li X, Li W, Zhou S, Wang G, *et al.* Characterization of the microenvironment of diabetic foot ulcers and potential drug identification based on scRNA-seq. *Front Endocrinol (Lausanne)* 2022;13:997880.
12. Zhou Z, Deng T, Tao M, Lin L, Sun L, Song X, *et al.* Snail-inspired AFG/GelMA hydrogel accelerates diabetic wound healing via inflammatory cytokines suppression and macrophage polarization. *Biomaterials* 2023;299:122141.
13. Mohsin F, Javaid S, Tariq M, Mustafa M. Molecular immunological mechanisms of impaired wound healing in diabetic foot ulcers (DFU), current therapeutic strategies and future directions. *Int Immunopharmacol* 2024;139:112713.
14. Xiao Y, Qian J, Deng X, Zhang H, Wang J, Luo Z, *et al.* Macrophages regulate healing-associated fibroblasts in diabetic wound. *Mol Biol Rep* 2024;51:203.
15. Ho J, Yue D, Cheema U, Hsia HC, Dardik A. Innovations in stem cell therapy for diabetic wound healing. *Adv Wound Care (New Rochelle)* 2023;12:626-43.
16. Choi D, Bakhtiari M, Pilcher W, Huang C, Thomas BE, Mumme H, *et al.* Single-cell analysis of debrided diabetic foot ulcers reveals dysregulated wound healing environment in non-hispanic black patients. *J Invest Dermatol* 2025;145:678-90.
17. Deng H, Li B, Shen Q, Zhang C, Kuang L, Chen R, *et al.* Mechanisms of diabetic foot ulceration: A review. *J Diabetes* 2023;15:299-312.
18. Aitchison SM, Frentiu FD, Hurn SE, Edwards K, Murray RZ. Skin wound healing: Normal macrophage function and macrophage dysfunction in diabetic wounds. *Molecules* 2021;26:4917.
19. Jhamb S, Vangaveti VN, Malabu UH. Genetic and molecular basis of diabetic foot ulcers: Clinical review. *J Tissue Viability* 2016;25:229-36.
20. Louiselle AE, Niemiec SM, Zgheib C, Liechty KW. Macrophage polarization and diabetic wound healing. *Transl Res* 2021;236:109-16.
21. Li Y, Li X, Ju S, Li W, Zhou S, Wang G, *et al.* Role of M1 macrophages in diabetic foot ulcers and related immune regulatory mechanisms. *Front Pharmacol* 2022;13:1098041.
22. Yu DM, Zhao J, Lee EE, Kim D, Mahapatra R, Rose EK, *et al.* GLUT3 promotes macrophage signaling and function via RAS-mediated endocytosis in atopic dermatitis and wound healing. *J Clin Invest* 2023;133:e170706.
23. Yang S, Wang S, Chen L, Wang Z, Chen J, Ni Q, *et al.* Neutrophil extracellular traps delay diabetic wound healing by inducing endothelial-to-mesenchymal transition via the hippo pathway. *Int J Biol Sci* 2023;19:347-61.
24. Huang X, Liang P, Jiang B, Zhang P, Yu W, Duan M, *et al.* Hyperbaric oxygen potentiates diabetic wound healing by promoting fibroblast cell proliferation and endothelial cell angiogenesis. *Life Sci* 2020;259:118246.
25. Lu Y, Liu X, Zhao J, Bie F, Liu Y, Xie J, *et al.* Single-cell profiling reveals transcriptomic signatures of vascular endothelial cells in non-healing diabetic foot ulcers. *Front Endocrinol (Lausanne)* 2023;14:1275612.
26. Theocharidis G, Baltzis D, Roustit M, Tellechea A, Dangwal S, Khetani RS, *et al.* Integrated skin transcriptomics and serum multiplex assays reveal novel mechanisms of wound healing in diabetic foot ulcers. *Diabetes* 2020;69:2157-69.
27. Guo S, Dipietro LA. Factors affecting wound healing. *J Dent Res* 2010;89:219-29.
28. Sorg H, Tilkorn DJ, Hager S, Hauser J, Mirastschijski U. Skin wound healing: An update on the current knowledge and concepts. *Eur Surg Res* 2017;58:81-94.
29. Peña OA, Martin P. Cellular and molecular mechanisms of skin wound healing. *Nat Rev Mol Cell Biol* 2024;25:599-616.
30. Fernandes A, Rodrigues PM, Pintado M, Tavaría FK. A systematic review of natural products for skin applications: Targeting inflammation, wound healing, and photo-aging. *Phytomedicine* 2023;115:154824.
31. Bonnici L, Suleiman S, Schembri-Wismayer P, Cassar A. Targeting signalling pathways in chronic wound healing. *Int J Mol Sci* 2023;25:50.
32. Villablanca EJ, Selin K, Hedin CR. Mechanisms of mucosal healing: Treating inflammatory bowel disease without immunosuppression? *Nat Rev Gastroenterol Hepatol* 2022;19:493-507.
33. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. *Nat Med* 2012;18:1028-40.
34. Catrina SB, Zheng X. Disturbed hypoxic responses as a pathogenic mechanism of diabetic foot ulcers. *Diabetes Metab Res Rev* 2016;32 Suppl 1:179-85.
35. Wang Q, Ying X, Huang Q, Wang Z, Duan S. Exploring the role of tRNA-derived small RNAs (tsRNAs) in disease: Implications for HIF-1 pathway modulation. *J Mol Med (Berl)* 2024;102:973-85.
36. Hayes PD, Alzuhr N, Curran G, Loftus IM. Topical oxygen therapy promotes the healing of chronic diabetic foot ulcers: A pilot study. *J Wound Care* 2017;26:652-60.
37. Pichu S, Sathiyamoorthy J, Krishnamoorthy E, Umapathy D, Viswanathan V. Impact of the hypoxia inducible factor-1 α (HIF-1 α) pro582ser polymorphism and its gene expression on diabetic foot ulcers. *Diabetes Res Clin Pract* 2015;109:533-40.
38. Monaci S, Coppola F, Giuntini G, Roncoroni R, Acquati F, Sozzani S, *et al.* Hypoxia enhances the expression of RNASET2 in human monocyte-derived dendritic cells: Role of PI3K/AKT pathway. *Int J Mol Sci* 2021;22:7564.
39. Taylor CT, Scholz CC. The effect of HIF on metabolism and immunity. *Nat Rev Nephrol* 2022;18:573-87.
40. Chen X, Li X, Zhang W, He J, Xu B, Lei B, *et al.* Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF- κ B pathway. *Metabolism* 2018;83:256-70.
41. Pichu S, Vimalraj S, Sathiyamoorthy J, Viswanathan V. Association of hypoxia inducible factor-1 alpha exon 12 mutation in diabetic patients with and without diabetic foot ulcer. *Int J Biol Macromol* 2018;119:833-7.
42. Baltzis D, Eleftheriadou I, Veves A. Pathogenesis and treatment of impaired wound healing in diabetes mellitus: New insights. *Adv Ther* 2014;31:817-36.
43. Hosty L, Heatherington T, Quondamatteo F, Browne S. Extracellular matrix-inspired biomaterials for wound healing. *Mol Biol Rep* 2024;51:830.
44. Geng K, Ma X, Jiang Z, Gu J, Huang W, Wang W, *et al.* WDR74 facilitates TGF- β /smad pathway activation to promote M2

- macrophage polarization and diabetic foot ulcer wound healing in mice. *Cell Biol Toxicol* 2023;39:1577-91.
45. Sutcliffe JE, Thrasivoulou C, Serena TE, Madden L, Richards T, Phillips AR, *et al.* Changes in the extracellular matrix surrounding human chronic wounds revealed by 2-photon imaging. *Int Wound J* 2017;14:1225-36.
 46. Wu PY, Yu YL, Zhao WR, Zhou B. Identifying and validating extracellular matrix-related gene CTSB in diabetic foot ulcer using bioinformatics and machine learning. *J Inflamm Res* 2024;17:5871-87.
 47. Tan CT, Liang K, Ngo ZH, Dube CT, Lim CY. Application of 3D bioprinting technologies to the management and treatment of diabetic foot ulcers. *Biomedicines* 2020;8:441.
 48. Fan R, Zhang C, Li F, Li B, McCarthy A, Zhang Y, *et al.* Hierarchically assembled nanofiber scaffolds with dual growth factor gradients promote skin wound healing through rapid cell recruitment. *Adv Sci (Weinh)* 2024;11:e2309993.
 49. Nikitovic D, Berdiaki A, Banos A, Tsatsakis A, Karamanos NK, Tzanakakis GN. Could growth factor-mediated extracellular matrix deposition and degradation offer the ground for directed pharmacological targeting in fibrosarcoma? *Curr Med Chem* 2013;20:2868-80.
 50. Chen Y, Wang X, Tao S, Wang Q, Ma PQ, Li ZB, *et al.* Research advances in smart responsive-hydrogel dressings with potential clinical diabetic wound healing properties. *Mil Med Res* 2023;10:37.
 51. Tavakoli S, Klar AS. Advanced hydrogels as wound dressings. *Biomolecules* 2020;10:1169.
 52. Mazini L, Rochette L, Admou B, Amal S, Malka G. Hopes and limits of adipose-derived stem cells (ADSCs) and mesenchymal stem cells (MSCs) in wound healing. *Int J Mol Sci* 2020;21:1306.
 53. Yang S, Li Y, Liu C, Wu Y, Wan Z, Shen D. Pathogenesis and treatment of wound healing in patients with diabetes after tooth extraction. *Front Endocrinol (Lausanne)* 2022;13:949535.
 54. Hofbauer LC, Busse B, Eastell R, Ferrari S, Frost M, Müller R, *et al.* Bone fragility in diabetes: Novel concepts and clinical implications. *Lancet Diabetes Endocrinol* 2022;10:207-20.
 55. Xiong Y, Lin Z, Bu P, Yu T, Endo Y, Zhou W, *et al.* A whole-course-repair system based on neurogenesis-angiogenesis crosstalk and macrophage reprogramming promotes diabetic wound healing. *Adv Mater* 2023;35:e2212300.
 56. Du J, Liu X, Wong CW, Wong KK, Yuan Z. Direct cellular reprogramming and transdifferentiation of fibroblasts on wound healing-fantasy or reality? *Chronic Dis Transl Med* 2023;9:191-9.
 57. Wan R, Weissman JP, Grundman K, Lang L, Grybowski DJ, Galiano RD. Diabetic wound healing: The impact of diabetes on myofibroblast activity and its potential therapeutic treatments. *Wound Repair Regen* 2021;29:573-81.
 58. Zhang X, Huang J, Zhao J, Li L, Miao F, Zhang T, *et al.* Exosome-mimetic vesicles derived from fibroblasts carrying matrine for wound healing. *Burns Trauma* 2024;12:tkae015.
 59. Jeganathan S, Fiorino C, Naik U, Sun HS, Harrison RE. Modulation of osteoclastogenesis with macrophage M1- and M2-inducing stimuli. *PLoS One* 2014;9:e104498.
 60. Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN. Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: The importance of metabolites. *Front Immunol* 2021;12:746151.
 61. Peng C, Zhang Y, Lang X, Zhang Y. Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy: New insights from bioinformatics analysis. *J Transl Med* 2023;21:66.
 62. Zhu Y, Xia X, He Q, Xiao QA, Wang D, Huang M, *et al.* Diabetes-associated neutrophil NETosis: Pathogenesis and interventional target of diabetic complications. *Front Endocrinol (Lausanne)* 2023;14:1202463.
 63. Kindlovits R, Pereira AM, Sousa AC, Viana JL, Teixeira VH. Effects of acute and chronic exercise in hypoxia on cardiovascular and glycemic parameters in patients with type 2 diabetes: A systematic review. *High Alt Med Biol* 2022;23:301-12.
 64. Kang Y, Xu L, Dong J, Yuan X, Ye J, Fan Y, *et al.* Programmed microalgae-gel promotes chronic wound healing in diabetes. *Nat Commun* 2024;15:1042.
 65. Guo J, Tian X, Liu H, Liu WJ. Editorial: Autophagy and hypoxia-inducible factor in diabetes. *Front Endocrinol (Lausanne)* 2023;14:1349432.
 66. Liu Y, Liu Y, He W, Mu X, Wu X, Deng J, *et al.* Fibroblasts: Immunomodulatory factors in refractory diabetic wound healing. *Front Immunol* 2022;13:918223.